Pharmacogenetic Testing for Fluoropyrimidines at Instituto Nacional de Câncer, Brazil

• References

• 1 Suarez-Kurtz G. Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA). Braz J Oncol 2021; 17: e-20210010
• 2 Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM. J Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018; 103 (02) 210-216
• 3 Lunenburg CATC, Van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, De Boer-Veger NJ, Buunk AM. et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 2020; 28 (04) 508-517
• 4 Naslavsky MS, Scliar MO, Yamamoto GL, Wang JYT, Zverinova S, Karp T. et al. Whole-genome sequencing of 1,171 elderly admixed individuals from São Paulo, Brazil. Nat Commun 2022; 13 (01) 1004
• 5 Botton MR, Hentschke-Lopes M, Matte U. Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population. Ann Hum Genet 2022; 86 (02) 102-107
• 6 Suarez-Kurtz G, Fernandes VC, Elias ABR. Implementation of DPYD genotyping in admixed American populations: Brazil as a model case. Clin Pharmacol Ther 2023; 114 (01) 23-24
• 7 Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FdSG. et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 2011; 6 (02) e17063
• 8 Suarez-Kurtz G. DPYD genotyping panels: Impact of population diversity. Clin Transl Sci 2024; 17 (04) e13805
• 9 Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y. et al. DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn 2024; 26 (10) 851-863
• 10 Turner AJ, Haidar CE, Yang W, Boone EC, Offer SM, Empey PE. et al. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clin Transl Sci 2024; 17 (01) e13699
• 11 Arquivo Brasileiro Online de Mutações (AbraOM) [Internet]. São Paulo: Centro de Estudos do Genoma Humano e Células-Tronco/Universidade de São Paulo. Available from: https://abraom.ib.usp.br/search.php
• 12 Suarez-Kurtz G. Letter to the Editor: Variant Coverage and Diagnostic Performance of Commercially Available DPYD Genotyping Tests in Brazil. J Natl Compr Canc Netw 2024; 22 (08) e247059
• 13 Nguyen DG, Morris SA, Chen A, Moore DC, Hanson SL, Larck C. et al. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series. J Natl Compr Canc Netw 2024; 22 (04) e247022
• 14 Pharmacogenomics Knowledge Base (PharmGKB) [Internet]. Stanford (CA): Stanford University. Available from: https://www.pharmgkb.org/labelAnnotations
• 15 Agência Nacional de Vigilância Sanitária (ANVISA). Xeloda [Internet]. Brasília: ANVISA. Available from: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=XELODAhttps://abraom.ib.usp.br/search.php
• 16 Agência Nacional de Vigilância Sanitária (ANVISA). Fluoruracila [Internet]. Brasília: ANVISA. Available from: https://consultas.anvisa.gov.br/#/bulario/?nomeProduto=FLUORURACILA